A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219063
- Lead Sponsor
- Novartis
- Brief Summary
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 844
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 26 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 6 weeks and 12 weeks Change from baseline in systolic blood pressure after 26 weeks Change from baseline in systolic blood pressure after 6 weeks and 12 weeks Blood pressure control target of < 140/90 mmHg after 6, 12, and 26 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States
Novartis Pharmaceuticals🇺🇸East Hanover, New Jersey, United States